- Details
- Matthew Galsky and Alicia Morgans share in a discussion on combination and maintenance strategies for muscle-invasive and metastatic bladder cancer and a number of reasons for combining immunotherapy with immune checkpoint blockade. These reasons include the concept of immunogenic cell death, depletion of suppressive immune cell subsets and independent drug action. Biographies: Matthew Galsky, MD,...
|
- Details
- Alicia Morgans interviews Andrea Apolo who details the trial design and current status of the Phase III adjuvant AMBASSADOR trial for patients with high-risk muscle-invasive bladder cancer (MIBC) and the need to develop additional treatment options for patients who are resistant to chemotherapy and develop recurrent disease. The AMBASSADOR trial aims to answer the question if there is a benefit to...
|
- Details
- (Length of Discussion: 12 min) A conversation between Petros Grivas and Alicia Morgans where they discuss the trials in the neoadjuvant, adjuvant and perioperative setting in advanced bladder cancer from ESMO 2018. They talk about the biology of the disease and considerations of available therapies, single vs combination, and for chemotherapy ineligible, as well as patients who opt out of chemothe...
|
- Details
- (Length of interview: 17 min) Cora Sternberg and Alicia Morgans provide a review of immunotherapy advances in both renal cell and bladder cancer. They review past and current trials providing insights into potential clinical and treatment applications. Biographies: Cora Sternberg MD, FACP Clinical Director of the Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, Former Chi...
|
- Details
- (Length of Discussion: 9 min) Evan Yu and Alicia Morgans have a diverse conversation highlighting the advances in the field of bladder cancer beyond IO and Checkpoint inhibition. They introduce a variety of therapy options being studied such as FGFR inhibition, antibody-drug conjugates, HER-2 and DNA repair. Biographies: Evan Yu, MD Alicia Morgans, MD Referenced in this discussion: Targeted Therap...
|
- Details
- (Length of Discussion: 21 min) Petros Grivas and Pedro Barata discuss how a recent study they performed applies to the field of metastatic urothelial cancer regarding the use of checkpoint inhibitors in a patient population outside the context of the clinical trial and the main objectives, results, and conclusion of that study as well as implications for the field. Biographies: Pedro Barata, MD, M...
|
- Details
- Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion with Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2 nd line therapy. A relevant discussion follows on a Phase 2 trial investigating 3 different dosing regimens of radiu...
|
- Details
- (Length of Discussion: 30 min) Arjun Balar, MD overviews his presentation from the American Association for Cancer Research Annual Meeting (AACR 2018) meeting on durvalumab plus tremelimumab, combination data in patients with metastatic urothelial cancer. A phase I, Study 10, of data which shows clinical activity with combination treatment in 2nd-line metastatic urothelial carcinoma. A study desig...
|
